Character Biosciences raises $93M with an eye on vision loss drugs
The startup is bringing into Phase 1 testing an experimental treatment it says could be more effective than marketed geographic atrophy medicines.
The startup is bringing into Phase 1 testing an experimental treatment it says could be more effective than marketed geographic atrophy medicines.
